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Perspective
C
hildren are often touted as 
being very important members 
of society because they 
represent our future. Optimizing their 
health outcomes has the potential for a 
huge impact on public health because 
children are at an early stage in the 
life trajectory. But it is often unclear 
how society allocates its resources 
or creates policies to ensure that it 
invests in children’s health. The under-
investment in pediatric clinical trials is 
a good example of how our resource 
allocation may be insufficient.
Over half of the pharmacological 
interventions we use for hospitalized 
children are off-label or unlicensed 
drugs [1,2]. The challenge for clinical 
care is that health care providers may 
fail to use medications that are indeed 
effective, or conversely, continue to use 
ineffective medications, or even those 
that bring unintended harm. Child 
health care providers must often rely 
on evidence that has been generated 
on adult populations [3]. However, 
both the safety and efficacy profiles 
of medications may be significantly 
different for children than adults 
due to differences in developmental 
physiology, disease pathophysiology, or 
developmental pharmacokinetics and 
pharmacodynamics [4,5].
The Challenges from the Past
History has shown that children may 
be exposed to serious unintended 
harms from medications if adequate 
research is not performed. Examples 
of such harm include the use of 
chloramphenicol for neonates 
producing the grey baby syndrome, 
the use of verapamil for treatment 
of infants with supraventricular 
tachycardia resulting in refractory 
hypotension and death, serious 
extrapyramidal dysfunction and 
bladder retention leading to 
hospitalization after domperidone, and 
many more [5–7]. 
To address the lack of 
randomized controlled trials 
(RCTs) and pharmacokinetic and 
pharmacodynamic evidence in 
children, Europe and the United 
States have enacted legislative and 
regulatory changes to encourage 
pharmaceutical companies to invest in 
research involving children, to provide 
the needed data on safety and efficacy 
of new agents [8,9]. The outcome of 
such legislative and regulatory changes 
has been an increase in the number of 
pediatric studies performed; however, 
a significant number of these studies 
have not yet been published [10]. An 
overall examination of the pediatric 
studies performed under this new 
legislation has shown that the types of 
drugs studied have tended to mirror 
those most commonly used by the adult 
market rather than drugs commonly 
used by children [11].
While there is evidence that children 
have been harmed by medication that 
has not been adequately studied, or 
by medication that has demonstrated 
differences in pharmacokinetics and 
pharmacodynamics in children as 
compared to adults, it has been more 
difficult to demonstrate significant and 
important differences in treatment 
effects between adults and children. In 
an examination of Cochrane systematic 
reviews dealing with interventions for 
diseases occurring in both children 
and adults, we identified 408 reviews. 
Only 52% of these included data from 
children. We could find no significant 
differences in effect sizes between 
these two groups, because all of the 
comparisons lacked statistical power 
with wide confidence intervals, and 
hence it was not possible to rule out 
clinically important differences [3]. 
Epilepsy as a Case Study
A new study by Philippe Ryvlin 
and colleagues in this issue of 
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS
Medicine:
Rheims S, Cucherat M, Arzimanoglou 
A, Ryvlin P (2008) Greater response to 
placebo in children than in adults: A 
systematic review and meta-analysis 
in drug-resistant partial epilepsy. PLoS 
Med 5(8): e166. doi:10.1371/journal.
pmed.0050166
In a systematic review of antiepileptic 
drugs, Philippe Ryvlin and colleagues find 
that children with drug-resistant partial 
epilepsy enrolled in trials seem to have a 
greater response to placebo than adults 
enrolled in such trials. PLoS Medicine  |  www.plosmedicine.org 1181 August 2008  |  Volume 5  |  Issue 8  |  e172
PLoS Medicine makes an important 
contribution to the question of 
whether there are differences in 
treatments effects between children 
and adults [12]. In an effort to 
investigate whether children and 
adults with drug-resistant partial 
epilepsy respond differently to active 
treatment versus placebo, these 
authors performed a comprehensive 
search for methodologically rigorous 
RCTs evaluating antiepileptic drugs 
as add-on treatment for both children 
and adults. Overall, the treatment 
effect for their primary outcome (i.e., 
50% responder rate) was significantly 
lower for children with a relative risk 
ratio of 0.67 (95% confidence interval 
0.51–0.89), explained by the higher 
rate of response in the placebo arms 
of the pediatric trials (19% versus 
9.9%, p < 0.001) [12]. 
Unfortunately, this study by Ryvlin 
and colleagues is limited by the 
relative paucity of pediatric data, 
with only five of the 32 trials having 
been performed on children and 
only one pediatric trial for each of 
the five agents examined. This study 
again underscores the relatively weak 
evidence base informing medical 
care in children compared with 
adults. Further, the comparison of 
treatment effects between adults and 
children was across and not within 
trials. Therefore the results could be 
explained by residual confounding, 
despite the meta-regression done by 
the authors, arising from differences 
in disease severity, drug dosages, 
outcome measures, and diagnostic 
categories.
Where to Go from Here
We know that the lack of trial evidence 
goes beyond neurological diseases 
to other childhood areas, such as 
pediatric cardiology, neonatology, 
pediatric intensive care, and oncology 
[2,13]. If we use publication of 
RCTs in general medical journals 
as a marker, it would appear the 
gap is widening between the annual 
number of published pediatric trials 
and adult trials [14]. Furthermore, a 
recent review of studies published in 
six leading medical journals showed 
that “studies involving adults were 
significantly more likely than child 
studies to be randomized, controlled 
trials, systematic reviews, or studies of 
therapies” [15]. 
The future agenda is 2-fold: while 
more research is required, careful 
attention must be paid to design and 
reporting. In terms of design, attention 
needs to be given to: 
Ensuring adequate sample sizes  s
that consider the potential placebo 
response and that are derived from 
calculations based on pediatric data, 
or taking into account relevant 
considerations when only adult data 
are available. 
Choice of objective, clinically  s
relevant endpoints that can be 
measured in a valid and reliable 
manner.
Choice of clinically appropriate  s
comparator (i.e., placebo versus 
other active agent). 
Identification of a priori subgroups  s
within the pediatric population that 
may show differential responses to 
treatment (e.g., infants, preschoolers, 
school-aged children, adolescents) 
and adequate power to avoid type II 
errors in such subgroup analyses. 
Child-focused attention to the  s
evaluation of adverse effects. Careful 
consideration in terms of sample size 
and length of follow-up is needed 
in order to avoid claims of safety 
when in fact the studies were under-
powered to detect rare events. The 
role of (prospective) meta-analysis to 
this end should be exploited.
Predefined tasks for committees that  s
monitor safety and adverse drug 
reactions. A recent literature review 
of therapeutic clinical trials involving 
oral and intravenous medicines in 
children from 1996 to 2002 showed 
that only 13 (2%) of 739 trials had 
safety monitoring committees [16]. 
Of the 739 trials, 523 (71%) trials 
reported adverse drug reactions 
(ADRs), and 151 (20%) of these 
trials reported a serious ADR. About 
11% of trials have a moderate or 
severe ADR. All pediatric clinical 
trials should have a safety monitoring 
committee.
The above design considerations 
need to be balanced with the ethical 
requirements for conducting research. 
However, where true equipoise 
exists, sufficient numbers of children 
need to be studied in order to 
provide valid estimates of treatment 
effects. Moreover, inadequately 
powered studies should themselves 
be considered a breach of ethical 
standards [17]. Recently, the creation 
of specialty-specific pediatric research 
networks in the United States, Canada, 
and Europe (The International 
Forum of Standards for Research with 
Children  lists some of them at http://
www.ifsrc.org/) was in part motivated 
by the need for multi-centered trials in 
order to ensure adequate and timely 
recruitment into trials. 
Conclusion
While more empirical evidence is 
needed to guide clinical practice for 
children, further research, such as 
the study by Ryvlin and colleagues, is 
important to inform the design and 
reporting of pediatric trials. Standards 
for the design and reporting of 
pediatric trials would contribute to the 
development of a methodologically 
strong and relevant evidence base for 
pediatric care. Moreover, adequate 
reporting will assist end-users in 
assessing the relevance and applicability 
of a study’s findings (http://www.
equator-network.org/).
Looking to the future, the evidence 
is mounting that there is an urgent 
need for high-quality RCTs in children, 
to ensure the medication we use is both 
safe and effective. To facilitate this 
development, an international group 
of clinical and methodological experts, 
of which the co-authors are members, 
have launched a forum around an 
international project to develop 
standards for research with children 
(http://www.ifsrc.org/). Membership 
of this forum is open to all who wish 
to contribute to the development of 
these standards, whether they are 
clinical researchers, basic researchers, 
regulators, patients, or parents.  
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